Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EffiCacy and safety of topical ketoroLac trOmethamine and sUbtenon triamcinolone acetonideand a “watch-and-wait” strategy for acute pseudophakic macular eDema: a randomized phase-3 trial Beurteilung der Wirksamkeit und Sicherheit von topischem Ketorolac-Trometamol, sub-Tenon Triamcinolonacetonid oder Observanz zur Behandlung des akuten pseudophaken Makulaödems: eine randomisierte Phase-3 Studie

Trial Profile

EffiCacy and safety of topical ketoroLac trOmethamine and sUbtenon triamcinolone acetonideand a “watch-and-wait” strategy for acute pseudophakic macular eDema: a randomized phase-3 trial Beurteilung der Wirksamkeit und Sicherheit von topischem Ketorolac-Trometamol, sub-Tenon Triamcinolonacetonid oder Observanz zur Behandlung des akuten pseudophaken Makulaödems: eine randomisierte Phase-3 Studie

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 29 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ketorolac (Primary) ; Triamcinolone (Primary)
  • Indications Retinal oedema
  • Focus Therapeutic Use
  • Acronyms CLOUD
  • Most Recent Events

    • 29 Jan 2020 Status changed from recruiting to discontinued.
    • 21 Feb 2018 Planned number of patients changed from 136 to 249.
    • 13 Oct 2017 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top